Tag Archives: ARQL

ArQule Inc. (ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program....More>>>

News about ARQL

Sabre Corp., L Brands Dip into Friday’s 52-Week Low Club
From:247wallst.com
February 17, 2017: Here are four stocks trading with relatively heavy volume among 30 equities making new 52-week lows in Friday’s session. On the NYSE, decliners led advancers by about 4 to 3 and on the Nasdaq decliners led advancers by about...Read More>>>